Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 12/2017

01-12-2017 | Review Article

Asymptomatic hyperuricemia: is it time to intervene?

Authors: Binoy J. Paul, K. Anoopkumar, Vinod Krishnan

Published in: Clinical Rheumatology | Issue 12/2017

Login to get access

Abstract

Whether to treat hyperuricemia uncomplicated by articular gout, urolithiasis, or uric acid nephropathy is an exercise in clinical judgment and universal agreement is lacking. Patients with coronary artery disease, chronic kidney disease, and early onset hypertension with persistent hyperuricemia are likely to be benefited with urate-lowering therapy. The paradigm of the causative association of hyperuricemia with cardiovascular and chronic kidney diseases seems to have progressed from skepticism to increasing evidence of a true relationship. Although such evidences are mounting, they are not enough to support pharmacotherapy for all patients with asymptomatic hyperuricemia. Further studies are needed to determine which patients are likely to get beneficial effects from pharmacotherapy and the minimum threshold of uric acid level required to experience clinical benefits.
Literature
1.
Oda M, Satta Y, Takenaka O et al (2002) Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 19:640–653CrossRefPubMed
2.
Kratzer JT, Lanaspa MA, Murphy MN et al (2014) Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci U S A 111:3763–3768CrossRefPubMedPubMedCentral
3.
Johnson RJ, Titte S, Cade JR et al (2005) Uric acid, evolution and primitive cultures. Semin Nephrol 2005(25):3–8CrossRef
4.
Watanabe S, Kang DH, Feng L et al (2002) Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40:355–360CrossRefPubMed
5.
6.
Alonso A, Rodriguez LA, Logroscino G et al (2007) Gout and risk of Parkinson disease: a prospective study. Neurology 69:1696–1700CrossRefPubMed
7.
Shen C, Guo Y, Luo W et al (2013) Serum urate and the risk of Parkinson’s disease: results from a meta-analysis. Can J Neurol Sci 40:73–79CrossRefPubMed
8.
Euser SM, Hofman A, Westendorp RG et al (2009) Serum uric acid and cognitive function and dementia. Brain 132(Pt 2):377–382 2009PubMed
9.
Lu N, Dubreuil M, Zhang Y et al (2016) Gout and the risk of Alzheimer’s disease: a population-based, BMI-matched cohort study. Ann Rheum Dis 75:547–551CrossRefPubMed
10.
Guerrero AL, Gutierrez F, Iglesias F et al (2011) Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. Neurol Sci 32:347–350CrossRefPubMed
11.
Moccia M, Lanzillo R, Costabile T et al (2015) Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study. J Neurol 262:961–967CrossRefPubMed
12.
Auinger P, Kieburtz K, McDermott MP (2010) The relationship between uric acid levels and Huntington’s disease progression. Mol Disord 25:224–228CrossRef
13.
Hershfield MS, Roberts LJ 2nd, Ganson NJ et al (2010) Treating gout with pegloticase, a PEGylatedurate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci USA 107:14351–14356CrossRefPubMedPubMedCentral
14.
Corry DB, Eslami P, Yamamoto K et al (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26:269–275CrossRefPubMed
15.
Kang DH, Han L, Ouyang X et al (2005) Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 25:425–433CrossRefPubMed
16.
Kang DH, Nakagawa T, Feng L et al (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888–2897CrossRefPubMed
17.
18.
Pillinger MH, Goldfarb DS, Keenan RT (2010) Gout and its comorbidities. Bull NYU Hosp Jt Dis. 68:199–203PubMed
19.
Goicoechea M, de Vinuesa SG, Verdalles U et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5:1388–1393CrossRefPubMedPubMedCentral
20.
Dehghan A, van Hoek M, Sijbrands EJ et al (2008) High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 31:361–362CrossRefPubMed
21.
Krishnan E, Pandya BJ, Chung L et al (2012) Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. Am J Epidemiol 176(2):108–116CrossRefPubMed
22.
Yoo TW, Sung KC, Shin HS et al (2005) Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 69(8):928–933CrossRefPubMed
23.
Campion EW, Glynn RJ, Delabry LO (1987) Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 82:421–426CrossRefPubMed
24.
Langford HG, Blaufox MD, Borhani NO et al (1987) Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 147:645–649CrossRefPubMed
25.
Lin KC, Lin HY, Chou P (2000) The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 27:1501PubMed
26.
Choi HK, Atkinson K, Karlson EW et al (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363:1277CrossRefPubMed
27.
Choi HK, Atkinson K, Karlson EW et al (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350:1093CrossRefPubMed
28.
Choi HK, Atkinson K, Karlson EW, Curhan G (2005) Obesity, weight change, hypertension, diuretic use, and risk of gout in men (2005) the health professionals follow-up study. Arch Intern Med 165:742CrossRefPubMed
29.
Yu T, Gutman AB (1967) Uric acid nephrolithiasis in gout: predisposing factors. Ann Intern Med 67:1133–1148CrossRefPubMed
30.
31.
Dincer HE, Dincer AP, Levinson DJ (2002) Asymptomatic hyperuricemia: treat or not to treat. Cleveland clinic J Med 69(8):594–608CrossRef
32.
Lu CC, Wu SK, Chung WS, Lin LH, Hung TW, Yeh CJ et al (2017) Metabolic characteristics and renal dysfunction in 65 patients with tophi prior to gout. Clinical Rheumatol 36(8):1903–1909
33.
34.
Grayson PC, Kim SY, LaValley M, Choi HK (2011) Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63(1):102–110CrossRef
35.
Perlstein TS, Gumieniak O, Williams GH et al (2006) Uric acid and the development of hypertension: the normative aging study. Hypertension 48:1031–1036CrossRefPubMed
36.
Mellen PB, Bleyer AJ, Erlinger TP et al (2006) Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 48:1037–1042CrossRefPubMed
37.
Krishnan E, Kwoh CK, Schumacher HR, Kuller L (2007) Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 49:298–303CrossRefPubMed
38.
39.
Leite MA (2011) Uric acid and fibrinogen: age-modulated relationships with blood pressure components. J Human Hypertens 25:476–483CrossRef
40.
Grayson PC, Kim SY, Lavalley M, Choi HK (2011) Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res 63:102–110CrossRef
41.
Silverstein D, Srivaths PR, Mattison P et al (2011) Serum uric acid is associated with high blood pressure in pediatric hemodialysis patients. Pediatr Nephrol 26:1123–1128CrossRefPubMed
42.
43.
44.
Kuwabara M, Niwa K, Nishi Y et al (2014) Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res 37:785–789. PubMed CrossRefPubMed
45.
Cui LF, Shi HJ, Wu SL et al (2017) Association of serum uric acid and risk of hypertension in adults: a prospective study of Kailuan Corporation cohort. Clin Rheum 36(5):1103–1110CrossRef
46.
Kuwubara M, Niwa K, Hisatone I et al (2017) Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases—Five-Year Japanese Cohort Study. Hypertension 69:1036–1044CrossRef
47.
Sundstrom J, Sullivan L, D’Agostino RB et al (2005) Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 45:28–33CrossRefPubMed
48.
49.
Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300:924–932CrossRefPubMedPubMedCentral
50.
Soletsky B, Feig DI (2012) Uric acid reduction rectifies pre hypertension in obese adolescents. Hypertension 60:1148–1156CrossRefPubMed
51.
Beattie CJ, Fulton RL, Higgins P (2014) Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension 64:1102–1107CrossRefPubMed
52.
Nakanishi N, Okamato M, Yoshida H et al (2003) Serum uric acid and the risk of developing hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol 18:523–530CrossRefPubMed
53.
Baldwin W, McRae S, Marek G et al (2011) Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 60:1258–1269CrossRefPubMedPubMedCentral
54.
Feig DI, Nakagawa T, Karumanchi SA et al (2004) Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 66:281–287CrossRefPubMed
55.
Murray T, Goldberg M (1975) Chronic interstitial nephritis: etiologic factors. Ann Intern Med 82:453–459CrossRefPubMed
56.
57.
58.
59.
60.
Obermayr R, Temmi C, Gutjahr G et al (2008) Elevated uric acid increases the risk for kidney disease. J Am SocNephrol 19(12):2407–2413
61.
Weiner D, Tighiouart H, Elsayed E, Griffith J, Salem D, Levey AS (2008) Uric acid and incident kidney disease in the community. J Am SocNephrol 19:1204–1211
62.
Whelton A, Macdonald PA, Chefo S, Gunawardhana L (2013) Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med 125(1):106–114CrossRefPubMed
63.
Sircar D, Chatterjee S, Wikhom R et al (2015) Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 66(6):945–950CrossRefPubMed
64.
Abbott RD, Brand FN, Kannel WB et al (1988) Gout and coronary artery disease: the Framingham study. J Clin Epidemiol 41(3):237–242CrossRefPubMed
65.
Reedman DS, Williamson DF, Gunter EW, Byers T (1995) Relation of serum uric acid to mortality and ischemic heart disease: the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 141:637–644CrossRef
66.
Culleton BF, Larson MB, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann.Int Med 131:7–13CrossRefPubMed
67.
68.
69.
70.
Kuo CF, Yu KH, See LC et al (2013) Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford) 52(1):111–117CrossRef
71.
72.
Capuano V, Marchese F, Capuano R et al (2017) Hyperuricemia as an independent risk factor for major cardiovascular events: a 10-year cohort study from Southern Italy. J Cardiovasc Med 18(3):159–164CrossRef
73.
Anker SD, Doehner W, Rauchhaus M et al (2003) Uric acid and survival in chronic heart failure. Circulation 107:1991–1199CrossRefPubMed
74.
75.
Becker MA, Jolly M (2006) Hyperuricemia and associated diseases. Rheum Dis Clin N Am 32:275–293CrossRef
76.
Burns CM, Wortmann RL (2017) Clinical features and treatment of gout. In: Firestein GS, Budd RC, Gabriel SC, McInnes IB, O'Dell JR (eds) Kelley and Firestein’s textbook of rheumatology, 10th edn. Elsevier, Philadelphia, p 1620–1644
77.
78.
79.
Park KY, Kim HJ, Ahn HS (2016) Effects of coffee consumption on serum uric acid: systematic review and meta-analysis. Semin Arthritis Rheum 45(5):580–586CrossRefPubMed
80.
Juraschek SP, Miller ER, Gelber AC (2011) Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken) 63(9):1295–1306 2011CrossRef
81.
Qin X, Li Y, He M et al (2017) Folic acid therapy reduces serum uric acid in hypertensive patients: a sub study of the China Stroke Primary Prevention Trial (CSPPT). Am J Clin Nutr 105(4):882–889CrossRefPubMed
82.
Hosoya T, Sasaki T, Ohashi T (2017) Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. Clinical Rheumatology 36(3):649–656CrossRefPubMed
83.
Stamp L, Dalbeth N (2017) Urate lowering therapy for asymptomatic hyperuricemia. A need for caution Sem Arthritis Rheum 46:457–464CrossRef
84.
Levy G, Cheetham TC (2015) Is it time to start treating asymptomatic hyperuricemia? Am J Kidney Dis 66(6):933–935CrossRefPubMed
85.
Ramirez MEG, Bargman JM (2017) Treatment of asymptomatic hyperuricemia in chronic kidney disease: a new target in an old enemy—a review. J Adv Res 8(5):551–554CrossRefPubMedPubMedCentral
Metadata
Title
Asymptomatic hyperuricemia: is it time to intervene?
Authors
Binoy J. Paul
K. Anoopkumar
Vinod Krishnan
Publication date
01-12-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 12/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3851-y

Other articles of this Issue 12/2017

Clinical Rheumatology 12/2017 Go to the issue

Brief Report

Coexistent rheumatoid arthritis and gout: a case series and review of the literature

Original Article

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis

Original Article

CD5+ B lymphocytes in systemic lupus erythematosus patients: relation to disease activity

Editorial

Psoriatic arthritis: is it time to treat-to-target or target to treat?

Original Article

Effect of vitamin D supplementation in chronic widespread pain: a systematic review and meta-analysis

Original Article

The association between genetic variation in interleukin-10 gene and susceptibility to Henoch-Schönlein purpura in Chinese children

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits